POSC370 Health-Related Quality of Life of Naratuximab Emtasine + Rituximab (N+R) in Second Line and Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): An Analysis of the Functional Assessment of Cancer Therapy Lymphoma (FACT-LYM) Measure and Mapped EQ-5D Values from a Phase II Trial

Autor: Orfanos, P, Peipert, J, Cella, D, Rechavi-Robinson, D, Gandola, A, Micallef, S, Brachet, S, Dymkowska, M
Zdroj: In Value in Health January 2022 25(1) Supplement:S245-S245
Databáze: ScienceDirect
Externí odkaz: